Price Alert

Apimeds Pharmaceuticals U... (APUS)

NYSE: APUS · Real-Time Price · USD

1.78

0.06 (3.49%)

At close: Oct 03, 2025, 1:51 PM

3.49% (1D)

Bid	1.76
Market Cap	22.37M
Revenue (ttm)	n/a
Net Income (ttm)	-3.71M
EPS (ttm)	-0.36
PE Ratio (ttm)	-4.94
Forward PE	n/a
Analyst	n/a
Dividends	n/a

Ask	1.85
Volume	31,342
Avg. Volume (20D)	133,339
Open	1.75
Previous Close	1.72
Day's Range	1.74 - 1.81
52-Week Range	1.37 - 4.00
Beta	n/a
Ex-Dividend Date	n/a

About APUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol APUS

Website n/a

Full Company Profile

News

2 weeks ago · businesswire.com

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the U...

1 month ago · businesswire.com

Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alaba...

2 months ago · businesswire.com

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally admi...